Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 383

1.

The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib.

Wörns MA, Koch S, Niederle IM, Marquardt JU, Nguyen-Tat M, Gamstätter T, Schuchmann M, Schulze-Bergkamen H, Galle PR, Weinmann A.

Dig Liver Dis. 2013 May;45(5):408-13. doi: 10.1016/j.dld.2012.10.010. Epub 2012 Nov 21.

PMID:
23182599
2.

Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib.

Inghilesi AL, Gallori D, Antonuzzo L, Forte P, Tomcikova D, Arena U, Colagrande S, Pradella S, Fani B, Gianni E, Boni L, Laffi G, Di Costanzo F, Marra F.

World J Gastroenterol. 2014 Jan 21;20(3):786-94. doi: 10.3748/wjg.v20.i3.786.

3.

Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.

Cho JY, Paik YH, Lim HY, Kim YG, Lim HK, Min YW, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC.

Liver Int. 2013 Jul;33(6):950-7. doi: 10.1111/liv.12168. Epub 2013 Apr 21.

PMID:
23601249
4.

Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma.

Kim HY, Park JW, Joo J, Kim H, Woo SM, Lee WJ, Kim CM.

J Gastroenterol Hepatol. 2013 Nov;28(11):1756-61. doi: 10.1111/jgh.12310.

PMID:
23800278
5.

Sorafenib treatment in Child-Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors.

Ogasawara S, Chiba T, Ooka Y, Kanogawa N, Saito T, Motoyama T, Suzuki E, Tawada A, Kanai F, Yokosuka O.

Invest New Drugs. 2015 Jun;33(3):729-39. doi: 10.1007/s10637-015-0237-3. Epub 2015 Apr 12.

PMID:
25861764
6.

Sorafenib for non-selected patient population with advanced hepatocellular carcinoma: efficacy and safety data according to liver function.

Zugazagoitia J, Manzano A, Sastre J, Ladero JM, Puente J, Díaz-Rubio E.

Clin Transl Oncol. 2013 Feb;15(2):146-53. doi: 10.1007/s12094-012-0902-3. Epub 2012 Aug 9.

PMID:
22875650
7.

Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.

Wörns MA, Weinmann A, Pfingst K, Schulte-Sasse C, Messow CM, Schulze-Bergkamen H, Teufel A, Schuchmann M, Kanzler S, Düber C, Otto G, Galle PR.

J Clin Gastroenterol. 2009 May-Jun;43(5):489-95. doi: 10.1097/MCG.0b013e31818ddfc6.

PMID:
19247201
8.
9.

Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib.

Pinter M, Sieghart W, Hucke F, Graziadei I, Vogel W, Maieron A, Königsberg R, Weissmann A, Kornek G, Matejka J, Stauber R, Buder R, Grünberger B, Schöniger-Hekele M, Müller C, Peck-Radosavljevic M.

Aliment Pharmacol Ther. 2011 Oct;34(8):949-59. doi: 10.1111/j.1365-2036.2011.04823.x. Epub 2011 Aug 24.

10.

Sorafenib in advanced hepatocellular carcinoma: a nationwide retrospective study of efficacy and tolerability.

Køstner AH, Sorensen M, Olesen RK, Grønbæk H, Lassen U, Ladekarl M.

ScientificWorldJournal. 2013;2013:931972. doi: 10.1155/2013/931972. Epub 2013 Jan 29.

11.

Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma.

Cammà C, Cabibbo G, Petta S, Enea M, Iavarone M, Grieco A, Gasbarrini A, Villa E, Zavaglia C, Bruno R, Colombo M, Craxì A; WEF study group.; SOFIA study group..

Hepatology. 2013 Mar;57(3):1046-54. doi: 10.1002/hep.26221. Epub 2013 Feb 12.

PMID:
23299720
12.

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.

Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, Galle PR, Santoro A, Beaugrand M, Sangiovanni A, Porta C, Gerken G, Marrero JA, Nadel A, Shan M, Moscovici M, Voliotis D, Llovet JM.

J Hepatol. 2012 Oct;57(4):821-9. doi: 10.1016/j.jhep.2012.06.014. Epub 2012 Jun 19.

13.

Sorafenib for Egyptian patients with advanced hepatocellular carcinoma; single center experience.

Abdel-Rahman O, Abdelwahab M, Shaker M, Abdelwahab S, Elbassiony M, Ellithy M.

J Egypt Natl Canc Inst. 2014 Mar;26(1):9-13. doi: 10.1016/j.jnci.2013.08.003. Epub 2013 Sep 16.

14.

Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib.

da Fonseca LG, Barroso-Sousa R, Bento Ada S, Blanco BP, Valente GL, Pfiffer TE, Hoff PM, Sabbaga J.

Med Oncol. 2014 Nov;31(11):264. doi: 10.1007/s12032-014-0264-5. Epub 2014 Oct 2.

PMID:
25273866
15.

Prognostic factors in patients with hepatocellular carcinoma refractory or intolerant to sorafenib.

Okuyama H, Ikeda M, Kuwahara A, Takahashi H, Ohno I, Shimizu S, Mitsunaga S, Senda S, Okusaka T.

Oncology. 2015;88(4):241-6. doi: 10.1159/000369351. Epub 2014 Dec 11.

PMID:
25503567
16.

Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy.

Estfan B, Byrne M, Kim R.

Am J Clin Oncol. 2013 Aug;36(4):319-24. doi: 10.1097/COC.0b013e3182468039.

PMID:
22547010
17.

Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib.

Ozenne V, Paradis V, Pernot S, Castelnau C, Vullierme MP, Bouattour M, Valla D, Farges O, Degos F.

Eur J Gastroenterol Hepatol. 2010 Sep;22(9):1106-10. doi: 10.1097/MEG.0b013e3283386053.

PMID:
20300004
18.

Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective comparison with previously known prognostic models.

Baek KK, Kim JH, Uhm JE, Park SH, Lee J, Park JO, Park YS, Kang WK, Lim HY.

Oncology. 2011;80(3-4):167-74. doi: 10.1159/000327591. Epub 2011 Jun 24.

PMID:
21701230
19.

Factors contributing to the overall survival in patients with hepatocellular carcinoma treated by sorafenib.

Tsukui Y, Mochizuki H, Hoshino Y, Kawakami S, Kuno T, Fukasawa Y, Iwamoto F, Hirose S, Yoshida T, Hosoda K, Suzuki Y, Hosoda K, Kojima Y, Hirose Y, Shindou K, Matsuda M, Yagawa S, Tawara A, Kobayashi M, Konishi T, Yamazaki T, Takahashi S, Fuji H, Enomoto N, Omata M.

Hepatogastroenterology. 2012 Nov-Dec;59(120):2536-9.

PMID:
22497953
20.

Determinants of survival after sorafenib failure in patients with BCLC-C hepatocellular carcinoma in real-world practice.

Lee IC, Chen YT, Chao Y, Huo TI, Li CP, Su CW, Lin HC, Lee FY, Huang YH.

Medicine (Baltimore). 2015 Apr;94(14):e688. doi: 10.1097/MD.0000000000000688.

Supplemental Content

Support Center